Reported 8 months ago
Taiwanese pharmaceutical company Mei Shi Chemical Pharmaceutical (1795) recently announced the decision to terminate the joint acquisition of the development, manufacturing, and exclusive global sales rights of NeuroRx Inc.'s bipolar disorder drug NRX-101 with Alvogen US. Due to certain conditions not being met as per the licensing agreement, Mei Shi and Alvogen US are no longer obligated to pay any milestone fees or sales royalties to NeuroRx. This decision was made after careful evaluation and review. NRX-101 is a product of NeuroRx, Inc., a subsidiary wholly owned by Nasdaq-listed company NRx Pharmaceuticals, Inc.
Source: YAHOO